Aduro Biotech, Inc. is a global immuno-oncology company that is developing new combination treatments based on three broad, proprietary immunotherapy platforms. These approaches modulate the tumor-immune system interface in multiple, complementary ways to potentially increase the efficacy of immunotherapy for
more patients.
Aduro’s novel immunotherapies are designed to induce highly targeted, potent and sustained immune responses against a variety of cancers.
Aduro Biotech is headquartered in Berkeley, California. Aduro Biotech Europe is a subsidiary based in Oss, Netherlands.